SCHEMBL8049313

SCHEMBL8049313

COC(=O)C[C@H](CCC(=O)Cl)C(=O)OC

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
TSHR P16473 5/20 0.38
SLC1A1 P43005 1/20 0.38
KMT2A Q03164 2/20 0.35
HSD17B10 Q99714 1/20 0.31
MGAM O43451 1/20 0.31
GAA P10253 1/20 0.31
SI P14410 1/20 0.31
MGAM2 Q2M2H8 1/20 0.31
MEN1 O00255 1/20 0.31
MME P08473 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
ALDH1A1 P00352 1/20 0.30
TP53 P04637 1/20 0.30
ZDHHC7 Q9NXF8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18391954 0.87 SLC1A1 (0.46) CA1CA2TSHRSLC1A1KMT2A
SCHEMBL526220 0.86 SLC1A1 (0.49) CA1CA2TSHRSLC1A1KMT2A
SCHEMBL16087778 0.83 FOLH1 (0.45) CA1CA2TSHRSLC1A1KMT2A
SCHEMBL3237660 0.80 KMT2A (0.48) CA1CA2TSHRSLC1A1KMT2A
SCHEMBL6363454 0.79 CA1 (0.42) CA1CA2TSHRSLC1A1KMT2A
SCHEMBL27817674 0.79 CA1 (0.52) CA1CA2TSHRSLC1A1KMT2A
SCHEMBL15237381 0.79 TSHR (0.42) TSHRSLC1A1KMT2AHSD17B10MGAM
SCHEMBL20013973 0.77 TSHR (0.41) TSHRSLC1A1KMT2AHSD17B10MGAM
SCHEMBL7349198 0.77 CA1 (0.41) CA1CA2TSHRSLC1A1KMT2A
SCHEMBL16388417 0.76 TSHR (0.55) CA1CA2TSHRSLC1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170015704-A1 AMINOTHIAZOLES AND THEIR USES NOVARTIS AG (CH) 2017-01-19 US disclosed
US-20170015704-A1 AMINOTHIAZOLES AND THEIR USES NOVARTIS AG (CH) 2017-01-19 US disclosed
US-9492496-B2 Aminothiazoles and their uses NOVARTIS AG (CH) 2016-11-15 US disclosed
US-9492496-B2 Aminothiazoles and their uses NOVARTIS AG (CH) 2016-11-15 US disclosed
US-20140274878-A1 AMINOTHIAZOLES AND THEIR USES NOVARTIS AG (CH) 2014-09-18 US disclosed
US-20140274878-A1 AMINOTHIAZOLES AND THEIR USES NOVARTIS AG (CH) 2014-09-18 US disclosed
WO-2009074605-A1 AMINOTHIAZOLES AND THEIR USES NOVARTIS AG (CH) 2009-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170015704-A1 AMINOTHIAZOLES AND THEIR USES ABAT, AADAT, BCAT2 CA1 4486/4885CA2 2495/4885TSHR 3438/4885
US-20140274878-A1 AMINOTHIAZOLES AND THEIR USES ABAT, AADAT, BCAT2 CA1 4486/4885CA2 2495/4885TSHR 3438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.